- Home
- SONN vs SCNI Comparison
SONN vs SCNI Comparison
Compare SONN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- SCNI
- Stock Information
- Founded
- SONN N/A
- SCNI 2003
- Country
- SONN United States
- SCNI Israel
- Employees
- SONN N/A
- SCNI N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SONN Health Care
- SCNI Health Care
- Exchange
- SONN Nasdaq
- SCNI Nasdaq
- Market Cap
- SONN 2.5M
- SCNI 3.0M
- IPO Year
- SONN N/A
- SCNI N/A
- Fundamental
- Price
- SONN $1.62
- SCNI $3.54
- Analyst Decision
- SONN Strong Buy
- SCNI
- Analyst Count
- SONN 2
- SCNI 0
- Target Price
- SONN $38.00
- SCNI N/A
- AVG Volume (30 Days)
- SONN 282.7K
- SCNI 6.9K
- Earning Date
- SONN 02-12-2025
- SCNI 11-22-2024
- Dividend Yield
- SONN N/A
- SCNI N/A
- EPS Growth
- SONN N/A
- SCNI N/A
- EPS
- SONN N/A
- SCNI 8.20
- Revenue
- SONN $18,626.00
- SCNI $452,000.00
- Revenue This Year
- SONN N/A
- SCNI N/A
- Revenue Next Year
- SONN N/A
- SCNI N/A
- P/E Ratio
- SONN N/A
- SCNI $0.43
- Revenue Growth
- SONN N/A
- SCNI N/A
- 52 Week Low
- SONN $1.41
- SCNI $2.23
- 52 Week High
- SONN $18.72
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- SONN 42.90
- SCNI 51.37
- Support Level
- SONN $1.64
- SCNI $3.45
- Resistance Level
- SONN $2.05
- SCNI $3.61
- Average True Range (ATR)
- SONN 0.17
- SCNI 0.12
- MACD
- SONN 0.03
- SCNI -0.00
- Stochastic Oscillator
- SONN 24.59
- SCNI 32.31
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.